ArriVent Biopharma, Inc. (AVBP)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$21.00+9.38%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge ArriVent Biopharma, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	6.05M
EPS	—	-1.093
Annual ending 2026-12-31
Revenue	—	125,000
EPS	—	-4.231
Annual ending 2027-12-31
Revenue	—	6.74M
EPS	—	-3.739

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain strong balance sheet to fund operations	ArriVent BioPharma has a stronger balance sheet supporting its pipeline.	Intact	Large dilutive equity raise or debt issuance beyond May 2026 levels	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net loss per share	A primary condition in ArriVent Biopharma, Inc.'s published investment case. The stated target is EPS loss improves to >= -$3.5 in FY27.	Under Pressure	EPS loss worsens or remains below -$4.0 in FY27	Diluted EPS: $-1.05 per share FY2026-Q2; GAAP. Published target: EPS loss improves to >= -$3.5 in FY27. Target period is not explicitly aligned with this observation. Source published Aug 12, 2026-1.05 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 38d93f0e-2d16-4c9e-ae10-9b2c6dc52631. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Enrollment progress in ALPACCA Phase 3 study	The company advances enrollment in its ALPACCA Phase 3 study.	Improving	Enrollment progress stalls or falls significantly behind schedule in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve initial revenue from product launches	A primary condition in ArriVent Biopharma, Inc.'s published investment case. The stated target is Revenue >= $42.7M in FY27.	Under Pressure	Revenue falls below $20M in FY27	Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $42.7M in FY27. Target period is not explicitly aligned with this observation. Source published Aug 12, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.74

$-3.42 → $-3.74 · observed estimates

FY2027 revenue$0.01B

$0.05B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.42	$45,781,917	7 / 6
2026-07-25	$-3.42	$45,781,917	7 / 6
2026-07-26	$-3.42	$45,781,917	7 / 6
2026-07-27	$-3.42	$45,781,917	7 / 6
2026-07-28	$-3.48	$46,997,660	9 / 8
2026-07-29	$-3.48	$46,997,660	9 / 8
2026-07-30	$-3.48	$46,997,660	9 / 8
2026-07-31	$-3.48	$46,997,660	9 / 8
2026-08-01	$-3.48	$46,997,660	9 / 8
2026-08-02	$-3.48	$46,997,660	9 / 8
2026-08-03	$-3.48	$46,997,660	9 / 8
2026-08-04	$-3.48	$46,997,660	9 / 8
2026-08-05	$-3.48	$46,997,660	9 / 8
2026-08-06	$-3.48	$46,997,660	9 / 8
2026-08-07	$-3.42	$45,781,917	6 / 6
2026-08-08	$-3.48	$46,997,660	9 / 8
2026-08-09	$-3.48	$46,997,660	9 / 8
2026-08-10	$-3.48	$46,997,660	9 / 8
2026-08-11	$-3.48	$46,997,660	9 / 8
2026-08-12	$-3.48	$46,997,660	9 / 8
2026-08-13	$-3.53	$48,725,890	9 / 7
2026-08-14	$-3.42	$45,781,917	6 / 6
2026-08-15	$-3.42	$45,781,917	6 / 6
2026-08-16	$-3.42	$45,781,917	6 / 6
2026-08-17	$-3.42	$45,781,917	6 / 6
2026-08-18	$-3.42	$45,781,917	6 / 6
2026-08-19	$-3.42	$45,781,917	6 / 6
2026-08-20	$-3.42	$45,781,917	6 / 6
2026-08-21	$-3.75	$30,278,182	7 / 7
2026-08-22	$-3.75	$30,278,182	7 / 7
2026-08-23	$-3.75	$30,278,182	7 / 7
2026-08-24	$-3.75	$30,278,182	7 / 7
2026-08-25	$-3.75	$30,278,182	7 / 7
2026-08-26	$-3.75	$30,278,182	7 / 7
2026-08-27	$-3.75	$30,278,182	7 / 7
2026-08-28	$-3.75	$30,278,182	7 / 7
2026-08-29	$-3.75	$30,278,182	7 / 7
2026-08-30	$-3.75	$30,278,182	7 / 7
2026-08-31	$-3.75	$30,278,182	7 / 7
2026-09-01	$-3.75	$30,278,182	7 / 7
2026-09-02	$-3.75	$30,278,182	7 / 7
2026-09-03	$-3.75	$30,278,182	7 / 7
2026-09-04	$-3.75	$30,278,182	7 / 7
2026-09-05	$-3.75	$30,278,182	7 / 7
2026-09-06	$-3.75	$30,278,182	7 / 7
2026-09-07	$-3.75	$30,278,182	7 / 7
2026-09-08	$-3.75	$30,278,182	7 / 7
2026-09-09	$-3.75	$30,278,182	7 / 7
2026-09-10	$-3.75	$30,278,182	7 / 7
2026-09-11	$-3.75	$30,278,182	7 / 7
2026-09-12	$-3.75	$30,278,182	7 / 7
2026-09-13	$-3.75	$30,278,182	7 / 7
2026-09-14	$-3.75	$30,278,182	7 / 7
2026-09-15	$-3.75	$30,278,182	7 / 7
2026-09-16	$-3.78	$30,278,182	7 / 7
2026-09-17	$-3.78	$30,278,182	7 / 7
2026-09-18	$-3.78	$30,278,182	7 / 7
2026-09-19	$-3.78	$30,278,182	7 / 7
2026-09-20	$-3.78	$30,278,182	7 / 7
2026-09-21	$-3.78	$30,278,182	7 / 7
2026-09-22	$-3.78	$30,278,182	7 / 7
2026-09-23	$-3.78	$30,278,182	7 / 7
2026-09-24	$-3.78	$30,278,182	7 / 7
2026-09-25	$-3.78	$30,278,182	7 / 7
2026-09-26	$-3.78	$30,278,182	7 / 7
2026-09-27	$-3.78	$30,278,182	7 / 7
2026-09-28	$-3.78	$30,278,182	7 / 7
2026-09-29	$-3.78	$30,278,182	7 / 7
2026-09-30	$-3.78	$30,278,182	7 / 7
2026-10-01	$-3.78	$30,278,182	7 / 7
2026-10-02	$-3.78	$30,278,182	7 / 7
2026-10-03	$-3.78	$30,278,182	7 / 7
2026-10-04	$-3.78	$30,278,182	7 / 7
2026-10-05	$-3.78	$30,278,182	7 / 7
2026-10-06	$-3.78	$30,278,182	7 / 7
2026-10-07	$-3.78	$30,278,182	7 / 7
2026-10-08	$-3.93	$9,576,000	7 / 6
2026-10-09	$-3.89	$7,314,500	7 / 7
2026-10-10	$-3.89	$7,314,500	7 / 7
2026-10-11	$-3.89	$7,314,500	7 / 7
2026-10-12	$-3.89	$7,314,500	7 / 7
2026-10-13	$-3.89	$7,314,500	7 / 7
2026-10-14	$-3.89	$7,314,500	7 / 7
2026-10-15	$-3.89	$7,314,500	7 / 7
2026-10-16	$-3.89	$7,314,500	7 / 7
2026-10-17	$-3.89	$7,314,500	7 / 7
2026-10-18	$-3.86	$6,740,455	7 / 7
2026-10-19	$-3.86	$6,740,455	7 / 7
2026-10-20	$-3.86	$6,740,455	7 / 7
2026-10-21	$-3.86	$6,740,455	7 / 7
2026-10-22	$-3.74	$6,740,455	7 / 6
2026-10-23	$-3.74	$6,740,455	7 / 7
2026-10-24	$-3.74	$6,740,455	7 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	12	0	0
2026-06-01	12	0	0
2026-07-01	12	0	0
2026-08-01	11	0	0
2026-09-01	11	0	0
2026-10-01	11	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades8 maintains

Recent actions · Sep 25–Oct 24 · 8 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 8 · prior Aug 17

$47.00 → $27.00-42.6%

GuggenheimOct 7

$18.00New observation · no comparable prior

BTIGOct 7

$29.00New observation · no comparable prior

Truist FinancialOct 6 · prior May 29

$45.00 → $18.00-60.0%

JefferiesOct 6

$18.00New observation · no comparable prior

$0$25.85$51.70

0 raises · 2 cuts · 0 unchanged · 3 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain strong balance sheet to fund operationsDirect metric needs a verified mapping
Reduce net loss per sharePublished status: Under Pressure
Enrollment progress in ALPACCA Phase 3 studyDirect metric needs a verified mapping
Achieve initial revenue from product launchesPublished status: Under Pressure

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.5%Typical daily move · historical

Downside history

-56.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ArriVent Biopharma, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, clinical-stage biotechnology business, where the thesis depends on developing treatments rather than established revenue. The long-term thesis is in a watch state: management has named recurring pipeline priorities, but evidence of delivery and clinical outcomes remains limited.

What's priced into ArriVent Biopharma, Inc.

The snapshot provides no valuation level or specific market expectations, so whether AVBP is cheap or expensive versus peers cannot be assessed. It also reports no valuation fragility warning, but that does not resolve the uncertainty around a loss-making business with no revenue reported for the latest quarter.

What the fundamentals likely do

Near term, losses and weak recent performance remain central, while the next earnings update carries elevated miss risk. The Q2 update showed ARR-217 entering dose optimization and ARR-002 advancing toward a first-patient dosing milestone; an agreement to license ARR-002 in Greater China is a specific partnership step, but clinical results and related revenue are not established. Total risk rose, and management’s firmonertinib trial priority has limited evidence of substantive progress in the supplied excerpts.

What ArriVent Biopharma, Inc. hinges on

The multi-year thesis hinges on clinical progress across firmonertinib and the ADC programs, and on whether the licensing partnership leads to further commercial progress. Near term, a guidance cut would be a negative signal, while continued earnings strength from sector peers could support healthcare-sector momentum; weakening jobs data could heighten recession concerns for cyclical names.